AbbVie Begins Construction of $223-M Biomanufacturing Expansion

AbbVie has broken ground on a new $223-million expansion of its Singapore manufacturing facility. AbbVie’s Singapore plant is a small-molecule and biologics manufacturing facility. The new investment will add 24,000 liters of biologics drug-substance capacity. 

With the announcement, AbbVie has invested more than $740 million in acquiring, modernizing and expanding its Singapore facility over the past 10 years. When fully operational, the expanded Singapore manufacturing facility – AbbVie’s only manufacturing site in Asia – will employ more than 500 people in manufacturing, quality assurance, supply chain, engineering and administration roles. This new investment is adding more than 100 jobs.   

Construction on the expansion will begin later this year (2024), with operations expected to commence in 2026. AbbVie’s Singapore manufacturing plant is a part of AbbVie’s Operations team, which consists of 14,000 employees working at more than 30 manufacturing, operations and logistics sites across the US, Asia, Europe, Puerto Rico, and South America. 

Source: AbbVie